CSL (ASX:CSL) update their R&D

Company News

by Rachael Jones

Biotech company CSL (ASX:CSL) is advancing its Research & Development (R&D) pipeline and capabilities to deliver a highly differentiated product portfolio mix, addressing a broader range of patients’ unmet needs.

During their annual R&D briefing to investors it was noted that the company is building on its leadership in plasma therapies through the identification of emerging new medicines.

They are collaborating with universities across the globe and have over 1,700 scientists working on therapies for challenging medical conditions.

In FY19, CSL invested US$832 million into its R&D portfolio, representing 9.7% of total revenues.

Shares in CSL (ASX:CSL) are trading 0.9 per cent lower at $275.38.

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.